Trial intelligence / Profile preview

ANAVEX2-73 in adult Rett syndrome

NCT03758924Phase 2Completed

Sponsor
Anavex Life Sciences Corp.
Start
Feb 2019
Primary completion
Oct 2020
Modality
Classical Binding Small Molecules
Countries
1
01

Overview

A Phase 2 trial of blarcamesine in Rett syndrome (RTT), sponsored by Anavex Life Sciences Corp.. Started Feb 2019; status: completed.

02

Drugs

blarcamesine
03

Conditions

Rett syndrome (RTT)

Beyond the preview

Go deeper on NCT03758924.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03758924.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call